Unmet need

The technology overcomes the limitation of current therapies that target a single mechanism of action

Market driver

A global ageing population will see 150 million people living with dementia by 2050

Market opportunity

Recent drug approvals fuelling growth that is forecast to reach $13.7B by 2030

UltraThera system

Therapeutic ultrasound, non-invasive, portable ISO13485 clinical research platform

Multimodal therapy

Removes toxic amyloid, toxic tau and restores memory and other brain functions

Preclinical data

Extensive preclinical data indicates clearance of pathological amyloid and tau protein aggregation and restoration of memory

IP and novel technology

Issued patents in the US and AU, pending EU and CA. Several PCT and provisional applications

Phase I trial

Safety and tolerability of low frequency ultrasound neuromodulation in Alzheimer's

Partnerships

In collaboration with The University of Queensland, UnIQuest, and key Medtech partners